- Home
- FGBI vs CTNM Comparison
FGBI vs CTNM Comparison
Compare FGBI & CTNM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- FGBI
- CTNM
- Stock Information
- Founded
- FGBI 1934
- CTNM 2009
- Country
- FGBI United States
- CTNM United States
- Employees
- FGBI N/A
- CTNM N/A
- Industry
- FGBI Savings Institutions
- CTNM
- Sector
- FGBI Finance
- CTNM
- Exchange
- FGBI Nasdaq
- CTNM Nasdaq
- Market Cap
- FGBI 121.9M
- CTNM 122.9M
- IPO Year
- FGBI N/A
- CTNM 2024
- Fundamental
- Price
- FGBI $8.28
- CTNM $4.76
- Analyst Decision
- FGBI
- CTNM Strong Buy
- Analyst Count
- FGBI 0
- CTNM 4
- Target Price
- FGBI N/A
- CTNM $22.50
- AVG Volume (30 Days)
- FGBI 20.6K
- CTNM 128.0K
- Earning Date
- FGBI 07-22-2025
- CTNM 08-12-2025
- Dividend Yield
- FGBI 0.47%
- CTNM N/A
- EPS Growth
- FGBI N/A
- CTNM N/A
- EPS
- FGBI 0.13
- CTNM N/A
- Revenue
- FGBI $81,247,000.00
- CTNM N/A
- Revenue This Year
- FGBI N/A
- CTNM N/A
- Revenue Next Year
- FGBI $3.38
- CTNM N/A
- P/E Ratio
- FGBI $61.50
- CTNM N/A
- Revenue Growth
- FGBI N/A
- CTNM N/A
- 52 Week Low
- FGBI $6.56
- CTNM $3.35
- 52 Week High
- FGBI $15.25
- CTNM $22.00
- Technical
- Relative Strength Index (RSI)
- FGBI 44.50
- CTNM N/A
- Support Level
- FGBI $7.40
- CTNM N/A
- Resistance Level
- FGBI $9.01
- CTNM N/A
- Average True Range (ATR)
- FGBI 0.31
- CTNM 0.00
- MACD
- FGBI -0.06
- CTNM 0.00
- Stochastic Oscillator
- FGBI 55.28
- CTNM 0.00
About FGBI First Guaranty Bancshares Inc.
First Guaranty Bancshares Inc provides personalized commercial banking services to its customers in Louisiana, through several banking facilities. The principal business activity of the company includes attracting deposits and investing it together with funds generated from operations and borrowings insecurities and in lending activities to serve the credit needs of its customer base. The company offers commercial real estate loans, commercial and industrial loans, construction and land development loans, agricultural and farmland loans, and to a lesser extent, consumer and multifamily loans.
About CTNM Contineum Therapeutics Inc. Class A Common Stock
Contineum Therapeutics Inc is a clinical stage biopharmaceutical company focused on discovering and developing novel, oral small molecule therapies for NI&I indications with high unmet need. Its internally-discovered drug candidates, PIPE-791 and PIPE-307, PIPE-791, is a novel, brain penetrant, small molecule inhibitor of the LPA1R in development for IPF and PIPE-307, is a novel, small molecule selective inhibitor of the muscarinic type 1 M1R, in development for depression and RRMS.